Nordicnanovector is a brand specializing in innovative targeted radionuclide therapies. With a focus on extending and improving the lives of patients with cancer, their mission is to deliver cutting-edge treatments in the field. Their flagship product, Betalutin®, is a novel CD37-targeting radioimmunotherapy that has gained recognition for its effectiveness.

Nordicnanovector has a strong commitment to scientific research, evident in their extensive collection of scientific publications, papers, and posters. They actively engage with investors and media, providing stock information, investor relations, press releases, reports, and presentations. The brand prides itself on its corporate governance, corporate social responsibility, and adherence to guidelines for executive remuneration.

Nordicnanovector recently made headlines with the acquisition of Thor Medical, further showcasing their dedication to expanding their capabilities. Moreover, they have an upcoming Annual General Meeting where important updates and discussions will be held. Overall, Nordicnanovector strives to make a significant impact in the field of targeted radionuclide therapies through their innovative products, high-quality research, and commitment to patient well-being